ResApp Health: New publication highlights challenges of diagnosing acute respiratory disease in emergency departments


View printable version

  • The first known assessment of diagnostic accuracy by emergency department clinicians for acute respiratory disease

  • The authors found that acute pediatric respiratory disease was frequently misdiagnosed, with over 45% of pneumonia cases missed.

Brisbane, Australia, November 19, 2021 – ResApp Health Limited (ASX: RAP), a leading digital health company that develops smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce the release of clinical study data analyzed from its Breathe Easy pediatric clinical study in the core peer group. revised journal, Frontiers in Pediatrics.

The flagship publication, titled “Misdiagnosis is Common in Acute Pediatric Respiratory Illness: A Prospective, Single-Blind Study of Diagnostic Accuracy in Australian Emergency Departments”1, uses data from the Breathe Easy pediatric clinical study to assess the diagnostic accuracy of emergency department clinicians in diagnosing acute pediatric respiratory disease, against the consensus of a panel of experts.

In the study, the authors analyzed data from 620 pediatric patients who presented to the emergency department and found that acute respiratory disorders were frequently misdiagnosed. While asthma and lower respiratory tract diseases were well identified (at rates of 91% and 86% respectively), over 45% of focal pneumonia cases, 35% of isolated upper respiratory tract infections, 23% cases of croup and 33% of cases of bronchiolitis were missed. by clinicians in the emergency department.

The authors concluded “In adequately resourced emergency departments, we have identified a hitherto unknown high rate of misdiagnosis for acute respiratory disorders in children, particularly in pneumonia and bronchiolitis. These errors can lead to preventable damage and the administration of inappropriate treatment.

Dr Paul Porter, author of the publication and scientific advisor to ResApp said: “Our work sheds light on the standard of care for the diagnosis of acute respiratory illness in the emergency department. The differential diagnosis of childhood respiratory illnesses is difficult because it relies on a complex mix of clinical and interpretive skills, aggravated by many illnesses with characteristics such as shortness of breath and wheezing. Although these illnesses are the most common reasons children are taken to the emergency room, our study shows that they are often misdiagnosed. “

Tony Keating, CEO and Managing Director of ResApp added: “These results highlight the clinical value ResAppDx brings to the assessment of patients with respiratory symptoms. For example, in the same data set, our cough-based pneumonia algorithm identified 87% of children with pneumonia. without the need for clinical examination or ResAppDx not only offers clinicians an objective and accurate diagnostic tool, but it has the potential to provide a high quality diagnosis, equal to or better than what is achieved in a well emergency department. endowed, globally, making it more accessible and affordable for everyone. “

1Porter P, Brisbane J, Tan, J, Bear N, Choveaux, J, Della, P, Abeyratne, U. Misdiagnosis is common in acute pediatric respiratory disease: a prospective, single-blind study of the accuracy of diagnosis in Australian emergency services. Before. Pediatrician (2021) 9: 1273.


About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of breathing problems without the need for additional accessories or hardware. Regulatory-approved and clinically validated ResApp products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency departments, and primary care; and SleepCheck, a smartphone app that allows consumers to self-assess their risk for sleep apnea. Both products are CE marked in Europe and TGA approved in Australia. For more information, please visit


Comments are closed.